Vaccines remain one of the most effective ways to prevent COVID-19 infections and serious disease. With vaccination rates around the globe still increasing, recent estimates suggest that the majority of adults could be vaccinated against COVID-19 by mid-2022.1 However, current vaccines may not optimally protect against new variants and protection from both natural and vaccine immunity may diminish over time.2
In the rapidly evolving landscape of the pandemic, we have taken a forward-looking approach to our vaccine development. In parallel to our ongoing phase 3 efficacy and safety study for our recombinant vaccine candidate, we have included a study of the vaccine as a potentially broadly protective booster to address evolving public health needs.
Our Commitment to Fighting COVID-19
Throughout the ongoing pandemic, we have joined forces to fight COVID-19